Stock Financial Ratios, Dividends, Split History

BFIN / BankFinancial Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price17.50
Volume29,300.00
Market Cap ($M)309.37
Enterprise Value ($M)278.66
Book Value ($M)197.63
Book Value / Share11.02
Price / Book1.56
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 17,932,223
Weighted Average Number Of Shares Outstanding Basic 18,279,899
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Shares Outstanding Basic Gross 18,429,018
Weighted Average Number Of Diluted Shares Outstanding 18,280,336
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.03
Return on Assets (ROA)0.01
Return on Equity (ROE)0.04
Balance Sheet (mrq) ($M)
Assets1,559.93
Liabilities1,361.58
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Brokerage Commissions Revenue0.00
Net Income9.00
Earnings Per Share Diluted0.49
Earnings Per Share Basic0.49
Cash Flow Statement (mra) ($M)
Cash From Operations22.73
Cash from Investing14.40
Cash from Financing14.40
Identifiers and Descriptors
CUSIP06643P104
Central Index Key (CIK)1303942

Split History

Stock splits are used by BankFinancial Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Why Meta Financial (CASH) Could Be Positioned for a Slump

2018-06-26 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Meta Financial Group, Inc. (CASH - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. (16-1)

The Zacks Analyst Blog Highlights: American Public, BankFinancial, Century Communities, CPI and IEC

2018-05-22 zacks
Chicago, IL – May 22, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include American Public Education, Inc. (APEI - Free Report) , BankFinancial Corporation (BFIN - Free Report) , Century Communities, Inc. (CCS - Free Report) , CPI Aerostructures, Inc. (59-0)

5 Top Stocks to Buy on Dollar's Newfound Strength

2018-05-21 zacks
The U.S. dollar maintains its strong rally since the start of the second quarter. The strength is primarily attributable to an uptick in U.S. government bond yields. Inflationary pressure owing to rising oil and raw material prices drove the U.S. 10-year bond yield higher. (11-0)

BankFinancial's (BFIN) CEO F. Morgan Gasior on Q1 2018 Results - Earnings Call Transcript

2018-05-06 seekingalpha
Good day ladies and gentlemen and welcome to the BankFinancial Corp’s First Quarter 2018 Earnings Conference Call. [Operator Instructions]. As a reminder, today’s program is being recorded. And now I’d like to introduce your host for today’s program, F. Morgan Gasior, Chairman and CEO. Please go ahead. (40-0)

CUSIP: 06643P104